RISPERIDONE

Brand name:

• Okedi®

Pharmaceutical company:

Servier Laboratories (AUST.) Pty. Ltd.

Condition/indication:
(therapeutic use)

• Schizophrenia

PBAC Submission type:

New PBS listing (Category 2)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2024

Related medicines:

• RISPERIDONE

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

06/06/2024

Lodgement of required documentation:

14/06/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 23/07/2024

Status:

Finalised

Government processes:

Commenced on 20/08/2024

Medicine listed on the PBS:

01/01/2025 (see PBS schedule)

---